Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Gout

• Recapturing Immune Tolerance to Pegloticase for the Management of Tophaceous Gout
• A Study of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection in Chinese Participants With Acute Gout
• Clinical Study of HR091506 Tablets in Treatment of Gout With Hyperuricemia in Adults
• Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients With Hyperuricemia
• Phase 2b/3 Study to Assess Efficacy and Safety of ABP-671 a Novel URAT1 Inhibitor in Participants With Gout
• A Therapeutic Confirmatory Study of Epaminurad Versus Febuxostat in Gout Patients
• A Exploratory Trial of WTX221 in Refractory Gout Patients
• Prednisolone Versus Colchicine for Acute Gout in Primary Care
• Phase 2B Double Blind, Dose Finding Study to Evaluate Safety and Efficacy of 3 Dosages of SAP 001.
• Phase II Study to Evaluate Efficacy and Safety of D-0120 Administered in Combination With Allopurinol in Subjects With Gout
• Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare
• A Phase Ib/II Study of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection in Chinese Participants With Acute Gout
• A Phase 3 Study to Assess the Safety and Efficacy of 12 Months Treatment With Tigulixostat Compared to Allopurinol in Gout Patients With Hyperuricemia
• A Phase 3 Study to Assess the Safety and Efficacy of 6 Months Treatment With Tigulixostat in Gout Patients With Hyperuricemia
• Clinical Study of SHR4640 Tablets Combined With Febuxostat Tablets in the Treatment of Primary Gout and Hyperuricemia
• An Innovative Chinese Herbal Formula for the Treatment of Gout
• A Trial of HR091506 Tablets in Treatment of Primary Gout With Hyperuricemia in Adults
• Clinical Study of Genakumab for Injection in Patients With Acute Gout
• To Evaluate Drug Interactions Between XNW3009, Febuxostat, and Colchicine in Patients With Gout
• A Study to Evaluate ALN-XDH in Healthy Subjects and Patients With Gout
• Phase 2 to Assess Efficacy and Safety in AR882 Alone or in Combination With Allopurinol in Patients With Tophaceous Gout
• Evaluation of Efficacy and Safety of AR882 in Gout Patients
• Immediate Prescription of a Hypouricemic Treatment, Febuxostat, Compared to Its Delayed Administration
• A Study to Evaluate Efficacy of Dotinurad and Febuxostat for the Treatment of Participants With Gout
• Phase IIa Study of ALLN-346 (Engineered Urate Oxidase) in Subjects With Hyperuricemia, Gout and Chronic Kidney Disease
• A Multicentre, Randomized, Double-blind, Allopurinol Controlled Study to Evaluate the Efficacy and Safety of SHR4640 in Subjects With Gout
• Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout
• Anakinra vs Prednisone to Treat Gout Flare in Patients With Chronic Kidney Disease Stage 4/5 or Renal Transplantation
• Treatment of Refractory Gout With ACTH or Methylprednisolone
• Study of of URC102 to Assess the Efficacy and Safety in Gout Patients
• A Phase 4, Open-label Study of KRYSTEXXA® (Pegloticase) Co-administered With Methotrexate (MTX) in Patients With Uncontrolled Gout (FORWARD OL)
• Low-dose Colchicine With or Without Stepwise Dose Titration of Febuxostat for Flare Prophylaxis in Gout
• A Study to Assess the Efficacy, Safety, and Pharmacokinetics of ABP-671 in Patients With Gout or Hyperuricemia
• A Study of SEL-212 in Patients With Gout Refractory to Conventional Therapy II
• A Study of SEL-212 in Patients With Gout Refractory to Conventional Therapy
• ACTH vs Betamethasone in Hospitalized Patients With Acute Gout
• Probiotics for Gout / Hyperuricemia: Randomized, Double-blind, Intervention, Parallel Controlled, Multicenter
• Phase 2a Study of AR882 Alone and in Combination With Febuxostat or Allopurinol in Gout Patients
• Topical Application to Relieve Gout: Efficacy Trial & Safety (TARGETS)
• Efficacy and Safety of Simiaowan in Prevention of Acute Flares in Chronic Gout Patients Initiating Febuxostat Therapy
• Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Evaluation of RPH-104 Administered at Different Doses to Patients With Acute Gout Attack
• A Study of Evaluating the Efficacy and Safety of SHR4640 in Subjects With Gout
• Placebo Controlled, Multiple Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAP-001 in Gout Patients
• Study of KRYSTEXXA® (Pegloticase) Plus Methotrexate in Participants With Uncontrolled Gout
• A Study to Assess Efficay and Safety of LC350189 Different Doses in Gout Patients With Hyperuricemia
• Relation Between Blood Concentration of Colchicine and Response to Colchicine Treatment in Gout Flare
• A Study to Compare the Efficacy of SEL-212 to KRYSTEXXA® in Gout Patients Refractory to Conventional Therapy
• Placebo Controlled, Dose Escalation Study to Evaluate Safety, Pharmacokinetics & Efficacy of SAP-001 in Gout Patients
• Pilot Study Evaluating The Efficacy Of Etanercept In Acute Gout
• The Percentage of Cases of Acute Treatment With Allopurinol in Gout Patients
• Study of FYU-981 in Hyperuricemic Outpatients With or Without Gout (Effect on Two Hyperuricemic Types)
• Febuxostat-Controlled, Double-Blind, Comparative Study of FYU-981 in Hyperuricemia With or Without Gout
• The Impact of Urate-lowering Therapy on Kidney Function (IMPULsKF)
• The Efficiency and Safety of Sodium Bicarbonate on Uric Acid in Patients With Asymptomatic Hyperuricemia or Gout
• A Phase 4 Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participants With Gout and Renal Impairment
• The Drug-Drug Interaction of SHR4640, Febuxostat and Colchicine in Patients With Gout
• Benzbromarone-Controlled, Double-Blind, Comparative Study of FYU-981 in Hyperuricemia With or Without Gout
• Study of FYU-981 in Hyperuricemia With or Without Gout
• Multi-Dose Safety/Pharmacodynamic Study of SEL-212/SEL-037 in Subjects With Symptomatic Gout & Elevated Blood Uric Acid
• Denosumab In Addition To Intense Urate-Lowering Therapy for Bone Erosions
• Efficacy and Safety of HuZhen Capsule for Treatment of Patients With Acute Gout
• CSP594 Comparative Effectiveness in Gout: Allopurinol vs. Febuxostat
• Anakinra vs. Steroids for the Treatment of Gout Attacks in Patients With Renal Disease (ASGARD): A Feasibility Study
• Study of URC102 to Assess the Safety and Efficacy in Gout Patients
• Intensive Urate Lowering Therapy of Febuxostat Compared to Allopurinol on Cardiovascular Risk in Patients With Gout
• Phase 2a RDEA3170 and Allopurinol Combination Study in Gout Subjects
• Bucillamine for the Treatment of Acute Gout Flare in Subjects With Moderate to Severe Gout
• A PD/Safety Study of RDEA3170 in Combination With Febuxostat for Treating Gout or Asymptomatic Hyperuricemia Patients
• Phase 2 Study of URC102 to Assess the Efficacy and Safety in Gout Patients
• A Study of AC-201 Controlled-Release Tablet (CR Tablet) in Patients With Gout
• RDEA3170 and Allopurinol Combination Study in Gout Subjects
• Evaluate the PK, PD, and Safety of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Patients With Gout
• RDEA3170 and Febuxostat Combination Study in Gout Subjects
• Efficacy, Safety And Tolerability Of PF-06743649 In Gout Subjects.
• Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
• Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout and Moderate Renal Impairment
• Safety and Efficacy of Oral Febuxostat in Subjects With Gout
• Phase II Dose Finding Study of RDEA3170 Versus Placebo in Japanese Patients With Gout or Asymptomatic Hyperuricemia
• Evaluate the Efficacy and Safety of Arhalofenate for Preventing Flares and Reducing Serum Uric Acid in Gout Patients
• Immune Molecular and Inflammatory Cytokines Dysfunction Analysis in Gout Patients With Different Urate Levels
• Colchicine Or Naproxen Treatment for ACute gouT
• Does Allopurinol Prolong a Treated, Acute Gout Flare?
• RDEA3170 Monotherapy in Subjects With Gout
• Lesinurad and Febuxostat Combination Extension Study in Gout
• Lesinurad and Allopurinol Combination Extension Study in Gout
• Allopurinol in Acute Gout
• A Study to Evaluate Safety and Efficacy of Oral Febuxostat in Patients With Gout
• A Proof-of-Concept Study of AC-201 to Prevent Gout Flares
• Open-Label Lesinurad Monotherapy Extension Study in Gout
• Study of Levotofisopam 50 mg Three Times a Day (TID) Administered for 7 Days on Hyperuricemia and Gout
• Combination Treatment Study in Subjects With Tophaceous Gout With Lesinurad and Febuxostat
• Combining Lesinurad With Allopurinol in Inadequate Responders
• Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
• Combining Lesinurad With Allopurinol in Inadequate Responders
• Study of the Safety and Efficacy of Long-Term Rilonacept Treatment for the Prevention of Gout Flares
• Efficacy and Safety of Colchicine for the Prevention of Gout Flares During the Initiation of Allopurinol
• Open Label Safety/Efficacy Study of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Gout Patients
• A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal Insufficiency
• Safety/Efficacy Study to Evaluate of MBX-102 in Combination With Allopurinol in Gout Patients
• Allopurinol Outcome Study
• Safety and Efficacy Study of MBX-102 in Treatment of Hyperuricemia in Patients With Gout
• Initiation of Allopurinol at First Medical Contact for Acute Attacks of Gout
• Study to Evaluate sUA-Lowering Activity, Safety & PK Interaction of Oral BCX4208 & Allopurinol Admin. in Subjects w/Gout
• Tranilast Plus Allopurinol in Patients With Moderate to Severe Gout (TAnGO)
• Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicines Including a 12 Week Extension and a 1 Year Open-label Extension Study.
• Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicine Including a 12 Weeks Extension and an Open-label 48 Weeks Extension Study
• Allopurinol Combination Study
• Study to Evaluate the Urate-Lowering Activity and Safety of Oral BCX4208 Administered in Subjects With Gout
• PREventative Study Against URate-Lowering Drug-Induced Gout Exacerbations (PRE-SURGE 2)
• Long Term Study of Canakinumab (ACZ885) in Patients With Gout
• Study Utilizing Rilonacept in Gout Exacerbations
• PREventative Study Against URate-lowering Drug-induced Gout Exacerbations 1
• Phase III Trial of Febuxostat in Korea Gout Patients
• A Study of the Efficacy of Canakinumab in Prevention of Acute Flares in Chronic Gout Patients Initiating Allopurinol Therapy (Core Study) and a Long-term Study of the Efficacy and Safety of Canakinumab in Patients With Gout (Extension Study)
• Targeted Dose Finding of Canakinumab (ACZ885) for Management of Acute Flare in Refractory or Contraindicated Gout Patients
• Re-exposure Study of Pegloticase Intravenous (i.v.) in Symptomatic Gout Patients
• MPC-004 for the Treatment of an Acute Gout Flare
• Efficacy and Safety of Oral Febuxostat in Participants With Gout
• Allopurinol Versus Febuxostat in Subjects Completing the Phase 3 Trials C02-009 or C02-010
• Dose-Response, Safety and Efficacy of Febuxostat in Subjects With Gout
• Long-Term Safety of Febuxostat in Subjects With Gout.
• Phase 3, Febuxostat, Allopurinol and Placebo-Controlled Study in Gout Subjects.
• A Study Evaluating the Effect of Etoricoxib and Indomethacin in the Treatment of Acute Gout (0663-081)(COMPLETED)
• Febuxostat Versus Allopurinol Control Trial in Subjects With Gout
• A Study of Persons With Gout Who Do Not Respond to or Are Allergic to Conventional Therapy